NanoViricides, Inc. (NYSE American: NNVC) has highlighted its broad-spectrum antiviral candidate NV-387 as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company noted that there are currently no approved vaccines or therapies specifically targeting the Bundibugyo virus strain, underscoring the urgent need for effective interventions.
According to the company, NV-387's host-targeted antiviral mechanism and oral formulation could offer significant advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. The drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola.
NanoViricides is a clinical-stage antiviral drug developer focused on creating special purpose nanomaterials for antiviral therapy. The company's novel nanoviricide class of drug candidates and technology are based on intellectual property and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs for all antiviral infections.
The company's lead drug candidate, NV-387, is a broad-spectrum antiviral drug being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. Another advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
NanoViricides is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The company holds a worldwide exclusive perpetual license to TheraCour's nanomedicine technology for several drugs with specific targeting mechanisms for the treatment of various human viral diseases.
To view the full press release, visit https://ibn.fm/aSF5Z.
